Evidence map›Paper›PMID 38090224›Full record

ArticleCase reports in nephrology2023

A Case of TAFRO Syndrome Developed after COVID-19 Vaccination.

Hitomi Hirose, Hitoshi Suzuki, Yukako Umezawa, Masako Iwasaki, Hiromitsu Fukuda, Hisatsugu Takahara, Shigeki Tomita, Yusuke Suzuki

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. TAFRO Syndrome and COVID-19.Biomedicines · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hitomi HiroseDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hitoshi SuzukiDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0002-1901-2111
Yukako UmezawaDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
Masako IwasakiDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hiromitsu FukudaDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hisatsugu TakaharaDepartment of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
Shigeki TomitaDepartment of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan.
Yusuke SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Juntendo University Urayasu Hospital · JPJuntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAFRO syndrome is a systemic inflammatory disorder, which is characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. It often presents with progressive clinical symptoms and can be fatal. COVID-19 vaccination is important to reduce the number of COVID-19-infected populations and lower the risk of becoming severe. However, serious adverse events have been reported. TAFRO syndrome that progresses after the COVID-19 mRNA vaccination has not yet been reported. A 45-year-old man developed fever, gross hematuria, renal dysfunction, pleural effusions, and ascites immediately after vaccination. This case fulfilled three major categories (thrombocytopenia, anasarca, and systemic inflammation) and two minor categories (renal insufficiency and myelofibrosis) and was diagnosed with TAFRO syndrome. High-dose steroid treatment was initiated, followed by prednisolone administration. After treatment, renal dysfunction and fluid retention were resolved. Universal vaccination against COVID-19 is important for lowering the risk of spreading COVID-19 infection. Several complications, such as renal, hematological, and heart diseases, have been reported; however, its pathogenesis is unclear. The possibility of various complications after the COVID-19 vaccination, including TAFRO syndrome, should be considered.

Identifiers

PMID38090224
PMCPMC10713246
OpenAlexW4389298287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.